New-onset dermatomyositis following SARS-CoV-2 infection and vaccination: a case-based review

[1]  A. Kreuter,et al.  Onset of amyopathic dermatomyositis following mRNA‐based SARS‐CoV‐2 vaccination , 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.

[2]  Adolfo Camargo Coronel,et al.  Dermatomyositis post vaccine against SARS-COV2 , 2022, BMC Rheumatology.

[3]  Jingxiang Huang,et al.  Dermatomyositis following COVID‐19 vaccination , 2022, Dermatologic therapy.

[4]  R. Ashinoff,et al.  COVID-19 vaccine-associated dermatomyositis , 2022, JAAD Case Reports.

[5]  C. Steenbergen,et al.  Increased Interleukin 18-Dependent Immune Responses Are Associated With Myopericarditis After COVID-19 mRNA Vaccination , 2022, Frontiers in Immunology.

[6]  Adrian Y. S. Lee,et al.  Development of anti-NXP2 dermatomyositis following Comirnaty COVID-19 vaccination , 2022, Postgraduate medical journal.

[7]  K. Vutipongsatorn,et al.  Inflammatory myopathy occurring shortly after severe acute respiratory syndrome coronavirus 2 vaccination: two case reports , 2022, Journal of Medical Case Reports.

[8]  W. Gouda,et al.  Dermatomyositis Following BNT162b2 mRNA COVID-19 Vaccination , 2022, Journal of Korean medical science.

[9]  P. Sethi,et al.  Myocarditis following COVID-19 mRNA vaccination , 2021, Proceedings.

[10]  D. Ye,et al.  New‐onset autoimmune phenomena post‐COVID‐19 vaccination , 2021, Immunology.

[11]  Ye-ming Wang,et al.  Presence of Anti-MDA5 Antibody and Its Value for the Clinical Assessment in Patients With COVID-19: A Retrospective Cohort Study , 2021, Frontiers in Immunology.

[12]  Ashok Kumar,et al.  COVID-19 vaccination-associated anti-Jo-1 syndrome , 2021, Reumatologia.

[13]  C. Haas,et al.  Macrophage activation syndrome in MDA5 antibody-positive dermatomyositis and COVID-19 infection , 2021, BMC Rheumatology.

[14]  N. Okiyama,et al.  Anti-NXP2 antibody-positive dermatomyositis developed after COVID-19 manifesting as type I interferonopathy , 2021, Rheumatology.

[15]  Z. Bahloul,et al.  Dermatomyositis following COVID-19 infection , 2021, La Revue de Médecine Interne.

[16]  F. Carneiro,et al.  Autoimmune hepatitis after COVID-19 vaccine – more than a coincidence , 2021, Journal of Autoimmunity.

[17]  A. Ahmadzadeh,et al.  Dermatomyositis‐lupus overlap syndrome complicated with cardiomyopathy after SARS‐CoV‐2 infection: A new potential trigger for musculoskeletal autoimmune disease development , 2021, Clinical case reports.

[18]  C. Crowson,et al.  Incidence, Prevalence, and Mortality of Dermatomyositis: A Population‐Based Cohort Study , 2021, Arthritis care & research.

[19]  C. Selmi,et al.  Environmental triggers for connective tissue disease: the case of COVID-19 associated with dermatomyositis-specific autoantibodies , 2021, Current opinion in rheumatology.

[20]  D. Duffy,et al.  Onset and Relapse of Juvenile Dermatomyositis Following Asymptomatic SARS-CoV-2 Infection , 2021, Journal of clinical immunology.

[21]  L. Ferris,et al.  COVID-19 vaccine safety and efficacy in patients with immune-mediated inflammatory disease: Review of available evidence , 2021, Journal of the American Academy of Dermatology.

[22]  M. Lynch,et al.  ANCA-Associated Vasculitis Following Pfizer-BioNTech COVID-19 Vaccine , 2021, American Journal of Kidney Diseases.

[23]  M. Hallek,et al.  Long‐lived macrophage reprogramming drives spike protein‐mediated inflammasome activation in COVID‐19 , 2021, EMBO molecular medicine.

[24]  F. Heppner,et al.  Association Between SARS-CoV-2 Infection and Immune-Mediated Myopathy in Patients Who Have Died. , 2021, JAMA neurology.

[25]  V. Ziaee,et al.  COVID-19 and myositis; true dermatomyositis or prolonged post viral myositis? , 2021, Pediatric Rheumatology.

[26]  G. Pinkus,et al.  Skeletal Muscle and Peripheral Nerve Histopathology in COVID-19 , 2021, Neurology.

[27]  P. Sfikakis,et al.  Effective DNA damage response after acute but not chronic immune challenge: SARS-CoV-2 vaccine versus Systemic Lupus Erythematosus , 2021, Clinical Immunology.

[28]  A. Roguin,et al.  Myocarditis following COVID-19 mRNA vaccination , 2021, Vaccine.

[29]  Anand N. Rajpara,et al.  Dermatomyositis in a COVID-19 positive patient , 2021, JAAD Case Reports.

[30]  M. García-Romero,et al.  Juvenile Dermatomyositis Triggered by SARS-CoV-2 , 2021, Pediatric Neurology.

[31]  Andreas Greinacher,et al.  Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination , 2021, The New England journal of medicine.

[32]  K. Fukunaga,et al.  COVID-19 shares clinical features with anti-melanoma differentiation-associated protein 5 positive dermatomyositis and adult Still's disease. , 2021, Clinical and experimental rheumatology.

[33]  P. Machado,et al.  Understanding and managing anti-MDA 5 dermatomyositis, including potential COVID-19 mimicry , 2021, Rheumatology International.

[34]  N. H. Borges,et al.  Onset of dermatomyositis in close association with COVID-19 - a first case reported , 2021, Rheumatology.

[35]  Y. Allenbach,et al.  The seasonality of Dermatomyositis associated with anti-MDA5 antibody: An argument for a respiratory viral trigger. , 2021, Autoimmunity reviews.

[36]  S. Chanda,et al.  MDA5 Governs the Innate Immune Response to SARS-CoV-2 in Lung Epithelial Cells , 2020, Cell Reports.

[37]  V. Werth,et al.  Environmental triggers of dermatomyositis: a narrative review , 2020, Annals of translational medicine.

[38]  T. Wu,et al.  Coronavirus vaccine development: from SARS and MERS to COVID-19 , 2020, Journal of Biomedical Science.

[39]  J. Woods,et al.  Covid-19–Associated Myopathy Caused by Type I Interferonopathy , 2020, The New England journal of medicine.

[40]  S. Baveja,et al.  Dermatomyositis during COVID-19 Pandemic (A Case Series): Is there a Cause Effect Relationship? , 2020, The Journal of the Association of Physicians of India.

[41]  C. Horlings,et al.  Muscle involvement in SARS‐CoV‐2 infection , 2020, European journal of neurology.

[42]  Takuya Inoue,et al.  The relationship between type 1 IFN and vasculopathy in anti-MDA5 antibody-positive dermatomyositis patients. , 2020, Rheumatology.

[43]  R. Waldman,et al.  Dermatomyositis: Clinical features and pathogenesis , 2020, Journal of the American Academy of Dermatology.

[44]  D. Weissman,et al.  mRNA vaccines — a new era in vaccinology , 2018, Nature Reviews Drug Discovery.

[45]  P. Lachenbruch,et al.  2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups , 2017, Arthritis & rheumatology.

[46]  P. Lachenbruch,et al.  2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups , 2017, Annals of the rheumatic diseases.

[47]  M. Vadala',et al.  Vaccination and autoimmune diseases: is prevention of adverse health effects on the horizon? , 2017, EPMA Journal.

[48]  G. Han,et al.  Increased Expression of the NOD-like Receptor Family, Pyrin Domain Containing 3 Inflammasome in Dermatomyositis and Polymyositis is a Potential Contributor to Their Pathogenesis , 2016, Chinese medical journal.

[49]  L. Marcos-Villar,et al.  The Cellular Factor NXP2/MORC3 Is a Positive Regulator of Influenza Virus Multiplication , 2015, Journal of Virology.

[50]  Y. Shoenfeld,et al.  Myositis and Vaccines , 2015 .

[51]  H. Orbach,et al.  Vaccines as a trigger for myopathies , 2009, Lupus.

[52]  P. Gregersen,et al.  An Interferon Signature in the Peripheral Blood of Dermatomyositis Patients is Associated with Disease Activity , 2007, Molecular medicine.

[53]  G. Pinkus,et al.  Interferon‐α/β–mediated innate immune mechanisms in dermatomyositis , 2005 .

[54]  Steven A Greenberg,et al.  Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. , 2005, Annals of neurology.